Next Pharmaceuticals Discloses Results of Nexrutine(R) Clinical Study

November 28, 2007

2 Min Read
Next Pharmaceuticals Discloses Results of Nexrutine(R) Clinical Study

SALINAS, Calif., Nov 29, 2007 (BUSINESS WIRE) -- Next Pharmaceuticals announced today the results of a clinical study on Nexrutine, conducted at The LaValle Metabolic Institute in Cincinnati, Ohio. Nexrutine is a proprietary blend of natural ingredients developed to address general aches and pains associated with physical activity and over-exertion. Out of the 401 participants 369 (92%) reported Nexrutine provided pain relief and 373 (93%) reported improvement in their overall condition. Three hundred sixty one (90%) reported Nexrutine helped provide a restful sleep.

The clinical trial was designed to be an open label, single center, clinical trial and the chief investigator was pharmacologist and naturopathic doctor, James LaValle, R.Ph., N.M.D., C.C.N., founder of The LaValle Metabolic Institute and author of numerous books, including Cracking the Metabolic Code and the Cox-2 Connection.

The primary objective of this pilot study was to study the safety and efficacy of Nexrutine. Dr. LaValle, enrolled male and female subjects in the study as appropriate from patients of his clinic. He enrolled the subjects in this study only if he recommended that they take Nexrutine to help manage pain and/or inflammation. Subjects were instructed to avoid taking Nexrutine in combination with any prescription drugs without the consent of their physician.

Next Pharmaceuticals (NP) was founded with the purpose of developing new, patented, natural ingredients for healthy living products in the dietary supplement, food and beverage industries. The goal of the company is to expand self-care and preventative health maintenance. NP has successfully developed six plant extracts, both patented and proprietary, plus Chromulin(TM), a new form of the essential trace mineral chromium for potentiating insulin. These products have significantly expanded the choices for self-care products, while providing large consumer brands with powerful product differentiation. Through the application of pharmaceutical technologies to natural botanical materials, including citrus fruits, NP has developed Relora(R) for relaxation and stress-related appetite control, Seditol(R) for better quality of sleep, Nexrutine(R) for inflammation, Citri-Z(R) for heart health; Flavoxine(TM) for healthy cholesterol, and Citrofen(TM) for mobility and comfort.

Subscribe and receive the latest updates on trends, data, events and more.
Join 57,000+ members of the natural products community.

You May Also Like